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GAF domains regulate the catalytic activity of certain vertebrate cyclic nucleotide phosphodiesterases
(PDEs) by allosteric, noncatalytic binding of cyclic nucleotides. GAF domains arranged in tandem are found
in PDE2, 5, 6, –10, and 11, all of which regulate the cellular concentrations of the second messengers
cAMP and/or cGMP. Nucleotide binding to GAF domains affects the overall conformation and the catalytic
activity of full-length PDEs. The cyclic nucleotide-bound GAF domains from PDE2,5,6, and10 all adopt
a conserved fold but show subtle differences within the binding pocket architecture that account for a large
range of nucleotide affinities and selectivity. NMR data and details from the structure of full-length nucleo-
tide-free PDE2A reveal the dynamic nature and magnitude of the conformational change that accompanies
nucleotide binding. The discussed GAF domain structures further reveal differences in dimerization proper-
ties and highlight the structural diversity within GAF domain-containing PDEs.Introduction
GAF domains form one of the largest and most widespread
domain families found in all kingdoms of life (Anantharaman
et al., 2001). Though rare in human proteins (among which
they are found only in PDEs), there are about 2000 GAF
domain-containing proteins (Schultz et al., 1998) in which GAF
domains have been shown to provide a variety of functions
including binding of small molecules, protein-protein interac-
tions (including dimerization), and other processes. However,
the vast majority of GAF domains have not been studied in any
detail, so their functions and ligand-binding potentials are, in
general, poorly understood. The acronym GAF is derived from
the first three protein families identified with this domain, namely
mammalian cGMP-dependent phosphodiesterases (PDEs),
Anabaena adenylyl cyclases, and E. Coli FhlA (Aravind and Pont-
ing, 1997). Similarities in sequence and structure reveal a distant
relationship to Per-ARNT-Sim (PAS) domains, another ligand-
binding superfamily with a similar fold (Aravind and Ponting,
1997; Ho et al., 2000).
A subfamily of GAF domains has evolved as cyclic nucleotide
(cNMP)-binding domains that allosterically regulate the catalytic
activity of cyclic nucleotide phosphodiesterases (PDEs—in par-
ticular PDE2, 5, 6, 10, and 11. These PDEs contain two
N-terminally located GAF domains, in which, according to the
nomenclature, the more N-terminal domain is labeled as GAF A
and the more C-terminal as GAF B. PDEs regulate the cellular
concentrations of the cyclic nucleotides cAMP and cGMP, both
of which function as essential secondmessengers andmodulate
a large number of cellular pathways (Beavo and Brunton, 2002).
Through their central role in many disease-related pathways,
PDEs are excellent drug targets and reached ‘‘blockbuster’’
status through the development of Viagra, Cialis, and Levitra,
all of which target PDE5 and aremainly used to treatmale erectile
dysfunction (Bender and Beavo, 2006; Omori and Kotera, 2007).StructureTo date, only one GAF domain in each PDE monomer has
been shown to bind cyclic nucleotide. The GAF A domains of
PDE5, 6, and 11, and the GAF B domain of PDE2 selectively
bind cGMP, whereas the GAF B domain of PDE10 selectively
binds cAMP. Binding of cGMP to the GAF domains from PDE2
and PDE5 increases the catalytic activity of the respective
PDE (Martins et al., 1982; Rybalkin et al., 2003a). In the case
of PDE5, allosteric cGMP binding enhances phosphorylation
through the cGMP-dependent protein kinase, which in turn
increases PDE5 activity and cGMP binding affinity of GAF A
(Francis et al., 2002; Rybalkin et al., 2003b). Binding of cGMP
to GAF A of PDE6 increases affinity for the Pg-subunit, an intrin-
sically disordered protein that inhibits the catalytic activity of
PDE6 when bound (Muradov et al., 2002; Song et al., 2008),
and alters the affinity for certain catalytic site inhibitors (Zhang
et al., 2008). Less is known about the GAF domain-dependent
regulatory mechanisms of PDE10 and PDE11. Binding of
cAMP to the GAF B domain of full-length PDE10A2 and binding
of cGMP to the GAF A domain of full-length PDE11A4 has
recently been demonstrated (Matthiesen and Nielsen, 2009).
Although direct activation by cyclic nucleotide binding of
PDE10 and PDE 11 has been suggested in a study with chimeric
protein constructs comprised of the catalytic domain of the
cyanobacterial adenylyl cyclase cyaB1 and the tandem GAF
domains from PDE10 and 11 (Gross-Langenhoff et al., 2006),
no direct activation was observed for the full-length PDE proteins
when assayed with cyclic nucleotide analogs (Matthiesen and
Nielsen, 2009). Further investigations are necessary to deter-
mine whether other factors (such as phosphorylation or mem-
brane attachment) control a potential GAF-dependent regulation
of the catalytic activity from PDE10 and PDE 11.
This review focuses on the atomic-level structures and
the derived functional implications of the cNMP-binding
GAF domains from PDEs. Nucleotide-binding determinants,17, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1551
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MinireviewTable 1. Reported Structures of Cyclic Nucleotide Binding GAF Domains from PDEs
Protein PDE2A PDE2A PDE5A PDE6C PDE10A
Organism mouse human mouse chicken human
PDB-code 1mc0 3ibj 2k31 3 dba 2zmf
Method X-ray X-ray NMR X-ray X-ray
Resolution 2.9 A˚ 3.0 A˚ n/a 2.6 A˚ 2.1 A˚
Nucleotide cGMP (GAF B) apo cGMP cGMP cAMP
Domain GAF A/B GAF A/B + cat. domain GAF A GAF A GAF B
Oligomer Dimer (GAF A) Monomer (GAF B)a Dimera Monomer Monomer Dimer
Reference (Martinez et al., 2002) (Pandit et al., 2009) (Heikaus et al., 2008) (Martinez et al., 2008) (Handa et al., 2008)
a apo-GAF B is dimeric in the crystal structure of the full-length human PDE2A but monomeric in the crystal structure of the cGMP-bound tandemGAF
domains from mouse PDE2A.cNMP-dependent conformational change, and dimerization pro-
perties of GAF domains are discussed. The review also high-
lights the diversity of GAF domains within the protein family of
cyclic nucleotide PDEs and gives an outlook for GAF domains
as potential drug targets.
Structure of the GAF Domain
The first reported atomic resolution structure of a GAF domain
was the crystal structure of the dimeric YKG9, a yeast protein
of unknown function (Ho et al., 2000). Though no ligand was
found to be bound to the protein, the majority of the overall
domain topology is preserved in the cNMP-binding GAF
domains from cyclic nucleotide PDEs. The first atomic resolution
structure of any PDE GAF domain was the 2.9 A˚ crystal structure
of the tandem GAF domains from PDE2A (Martinez et al., 2002).
The structure revealed a parallel homodimer in which GAF A
contains no ligand butmakes dimerization contact with a second
GAF A, whereas GAF B does not contribute to the dimerization
interface but binds cGMP in a deeply buried pocket. In contrast,
the tandem GAF domains from the cyanobacterial adenylyl
cyclase cyaB2 form an antiparallel dimer in which GAF A from
one protomer makes dimerization contact with GAF B from
a second protomer and vice versa. Further, both GAF A and B
of cyaB2 contain cAMP-binding sites (Martinez et al., 2005),
a fact that stands in contrast to the tandem GAF domain units
of PDEswhere only one GAF domain (either GAF A or B) contains
the cNMP binding site.
In the past year, three new cNMP-bound PDE GAF domain
structures have been reported (Table 1). Our laboratories pre-
sented a NMR solution structure of cGMP-bound PDE5A GAF
A (Heikaus et al., 2008) and a crystal structure of cGMP-bound
PDE6CGAF A (Martinez et al., 2008), while a structural genomics
consortium reported a crystal structure of cAMP-bound PDE10A
GAF B (Handa et al., 2008).
All reported structures from cyclic nucleotide-binding GAF
domains reveal that GAF domains consist of a core of a six-
stranded antiparallel b sheet with the strand order 3-2-1-6-5-4
and four a helices (Figures 1A and 1B). A fifth a helix (a1) is often
packed against the domain and may take part in domain dimer-
ization (Figures 2A and 2B), but it is not essential for the minimal
and stably folded GAF domain entity because it is not part of the
PDE5A GAF A structure. The central b sheet is a dividing plane
with helices a2 and a5 (and the N and C termini, respectively)1552 Structure 17, December 9, 2009 ª2009 Elsevier Ltd All rights ron one face and helices a3 and a4 on the other face. The latter
face and helices a3 and a4 form the cNMP binding site. The
structures of the GAF A domains from PDE5A and PDE6C also
contain a short a-helical turn that lies between b2 and b3, termed
a2/3 (Figure 1B) (Heikaus et al., 2008; Martinez et al., 2008).
GAF Domains as Dimerization Interfaces
All PDEs are dimeric and contain a conserved C-terminal cata-
lytic domain, but differ in their family-specific N-terminal regula-
tory domains (Bender and Beavo, 2006). Monomeric catalytic
domains have been shown to be catalytically active (Fink et al.,
1999), so the functional significance of the dimerization of
PDEs remains unexplained. Several biochemical studies using
a series of PDE constructs and the discussed GAF-domain
structures establish the tandem GAF domains (potentially
including the N-terminal sequences) as the site of tight dimeriza-
tion (Blount et al., 2006; Heikaus et al., 2008; Muradov et al.,
2003; Weeks et al., 2007; Zoraghi et al., 2005).
This is supported by low-resolution electron microscopy
images (Kajimura et al., 2002; Kameni Tcheudji et al., 2001) in
which full-length PDE5 and PDE6 both appear to be arranged
as parallel dimers with contacts between GAF A and B domains,
respectively. Consistent with this interpretation, the first high-
resolution crystal structure of any full-length PDE enzyme
reveals that the cyclic nucleotide-free PDE2A enzyme forms
a parallel homodimer (Pandit et al., 2009). In particular, the con-
necting helices between GAF A and B, and between GAF B and
the catalytic domain serve as the main dimerization interfaces
in the cGMP-free PDE2. This stands in contrast to the earlier
reported crystal structure of the cGMP-bound tandem GAF
domains (without the catalytic domain) from PDE2A in which
the cGMP-bound GAF B domain makes no dimerization contact
(Martinez et al., 2002), whereas GAF A forms a tight dimerization
interface via its helices a1 and a5 (Figure 2A) that is essentially
identical in both PDE2A crystal structures. Though a large
cGMP-dependent conformational change (see below) may influ-
ence the dimerization properties of GAF B and the GAF domain-
connecting helix, it is more likely that the monomeric GAF
B domain observed in the crystal structure of the tandem GAF
domains is due, at least in part, to crystal packing and that
GAF B is in fact dimeric in both states. This idea is further sup-
ported by the crystal structure of the PDE10A GAF B domain in
which dimerization is also provided by helices a1 and a5, whicheserved
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MinireviewFigure 1. Structures of the cNMP-Bound PDE GAF Domains
(A) Structures of the cNMP-bound GAF domains from PDE2A, PDE5A, PDE6C, and PDE10A. a helices are shown in red, b strands in blue, and loops in gray.
cNMP is shown in yellow sticks.
(B) Topology of GAF domain. Elements not universally present in the structures are shown in gray. Helix a1 is not present in the solution structure of PDE5AGAF A
or the crystal structure of PDE2A GAF B, whereas helix a2/3 is not present in the structures from PDE2A GAF B and PDE10A GAF B.
(C) Sequence alignment of cNMP-binding GAF domains from PDEs. Conservation was determined by ClustalW (Thompson et al., 1994), with identical residues
highlighted in red, highly conserved residues in orange, and weakly conserved residues in yellow. The sequence of human PDE11A GAF A is shown for
comparison.make extensive contact with a second GAF B protomer and are
both packed against the rest of the domain via helix a2.
Together, the three helices from each protomer form a six-helix
bundle of parallel helices (Figure 2B). Although the equivalentStructurehelices provide the dimerization contacts in both PDE2A GAF
A and PDE10A GAF B (and PDE2 GAF B) domains, the exact
helical arrangement and domain orientation significantly differ
(Figures 2A and 2B).Figure 2. Dimerization Interfaces of PDE2A
GAF A and PDE10A GAF B
(A) Structure of the homodimer formed by PDE2A
GAF A. Protomers are shown in gray and green.
(B) Structure of the homodimer formed by PDE10A
GAF B. Protomers are shown in gray and orange.
Two different angles are shown with right panel
rotated by 90 around the x axis toward the
viewing plane. The gray PDE10A GAF B domain
is structurally aligned with the gray PDE2A GAF
A domain and shown in identical orientations.17, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1553
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isolated cGMP-bound GAF A domain constructs of PDE5A
(including helices a2, a5) and PDE6C (including helices a1, a2,
a5) used for the respective structure determinations are both
monomeric (Heikaus et al., 2008; Martinez et al., 2008). There-
fore, other sequence elements located N- and C-terminal of
the GAF A domain are likely necessary for tight dimerization of
the PDE5 and PDE 6 enzymes as indicated by several studies
(Heikaus et al., 2008; Muradov et al., 2003; Zoraghi et al., 2005).
The structures of PDE GAF domains determined to date high-
light that there are several modes of GAF domain dimerization
as exemplified by PDE10 GAF B and PDE2 GAF A. Based on the
available structural and biochemical data, the consensus is that
all tandem GAF domains from PDEs form parallel dimers with
extensive dimerization interfaces between the domain-connect-
ing helices. The antiparallel dimerization of the tandem GAF
domains from the Anabaena adenylyl cyclase may therefore be
limited to evolutionarily lower organisms (Martinez et al., 2005).
The unique properties and orientations of the various PDE dimer-
ization interfacesmay provide amechanism to favor homodimeri-
zation incells that expressmultipleGAF-containingPDEs. Though
the structure of PDE2A tandem GAF plus catalytic domains
suggests that GAF domain dimerization is an essential regulator
of catalytic activity (Pandit et al., 2009), it remains to be shown
whether other regulatory processes alter the dimerization pro-
perties of the full-length enzymes. To answer this question, struc-
turesof identical protein constructs (ideally full-length) in activated
and nonactivated form are necessary (cNMP-bound versus
cNMP-free and/or phosphorylated versus unphosphorylated).
Cyclic Nucleotide Recognition and Binding Mode
The tandem GAF domains of PDE2, 5, and 6 have low nano-
molar affinities for cGMP (KD% 10 nM) but vary in their nucleotide
Figure 3. Cyclic Nucleotide Recognition
(A) Binding pocket interactions between cGMP
and PDE2A GAF B.
(B) Binding pocket interactions between cGMP
and PDE5A GAF A.
(C) Binding pocket interactions between cGMP
and PDE6C GAF A.
(D) Binding pocket interactions between cAMP
and PDE10A GAF B.
(E) Interaction between a2/3 and Asn116 in PDE6C
GAF A. Ser121 and Asn126 make hydrogen bond
contacts to Asn116, which in turn makes nucleo-
tide-specific contact with cGMP.
(F) PDE10A GAF B does not contain a2/3. The
motion range of Asp305 appears less restricted
and it is rotated out to accommodate Arg286,
which in turn makes nucleotide-specific contact
with cAMP.
selectivity.GAFA fromPDE6has thehigh-
est cGMP selectivity with a preference for
cGMP over cAMP of at least 10,000-fold
(Hebert et al., 1998; Huang et al., 2004),
whereas PDE5A GAF A has a cGMP
selectivity of several thousand-fold (Hei-
kaus et al., 2008). PDE2A GAF B is only
moderately selective with a 10-30-fold
preference for cGMP (Wu et al., 2004).
No affinities for nucleotide binding to PDE10A GAF B or
PDE11A GAF A have been reported to date. The affinity of
PDE10A GAF B is likely in the nanomolar range (based on its
slow off-rate) as it binds cAMP from the Escherichia coli cells
during expression and crystallizes bound to cAMP without the
addition of cAMP (Handa et al., 2008). In all cGMP-binding GAF
domains, the cGMP affinities are similarly high (in the low nano-
molar range) but the cAMP affinities differ significantly, indicating
that high-selectivity GAF domains contain certain negative deter-
minants that select against cAMP. From studies using constructs
of various length, it has become evident that affinities for isolated
(or tandem) GAF domains are often higher than for the full-length
enzymes (e.g., full-length PDE5 has cGMP affinity of 200 nM,
whereas the tandem GAF domains have an affinity of 2-10 nM
(Heikaus et al., 2008; Zoraghi et al., 2005)). This indicates that
additional elements of the full-length enzymes (such as the
N-terminal extension) can lower the cNMP affinity of the GAF
domains, presumably by stabilizing the apo-form of the domain
(Bruder et al., 2006).
In all reported GAF domain structures, the cyclic nucleotide is
deeply buried. The binding pocket is comprised of the six-
stranded b sheet, which provides the floor of the binding pocket,
and a helices a3 and a4, which provide the roof of the binding
pocket (Figure 1A). The helical dipole at the N terminus of a3
binds the cyclic phosphate group. There are also several
hydrogen bonds between protein-backbone atoms and the
phosphate oxygens (Figures 3A-3D). Hydrogen bond networks
and hydrophobic interactions between side chains and the
invariant part of the nucleotides provide important binding
energy that yields the observed nanomolar binding affinities for
the respective nucleotide.
Selectivity for cGMP and cAMP is provided by intermolecular
hydrogen bonds to the variant nucleotide moieties (i.e., the1554 Structure 17, December 9, 2009 ª2009 Elsevier Ltd All rights reserved
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(A) cGMP-free PDE2A GAF B. Electron density could not be traced for the b4-a4-loop, a4, and the b2-b3-loop indicating structural disorder as highlighted by the
dotted circles.
(B) cGMP-bound PDE2A GAF B. cGMP is shown in sticks with carbon atoms in yellow.substitutions at C6 (carbonyl in cGMP, amino-group in cAMP),
N1 (NH in cAMP), and C2 (amino-group in cGMP) of the nucleo-
tide base (Figures 3A-3D)). A single residue provides two cGMP-
specific hydrogen bond contacts (one from the main chain to
O6, one from the side chain to N1) in the cGMP-specific GAF
domains from PDE2A, PDE5A, and, PDE6C (Figures 3A-3C
and 3E). This residue is a conserved Asp in PDE2A and
PDE5A, and an Asn in PDE6C. In contrast, the Asp in the analo-
gous position in PDE10A is rotated away from the binding pocket
in the cAMP-bound PDE10A GAF B structure allowing an Arg to
make hydrogen bond contact with the N1-atom of cAMP instead
(Figures 3D and 3F). In PDE2A, mutation of Asp439 causes loss
of nucleotide selectivity so that cAMP and cGMP both bind with
essentially the same affinity (Wu et al., 2004). Mutation of Asp196
to an Ala in PDE5A leads to a complete switch of selectivity from
cGMP to cAMP in GAF A constructs (Heikaus et al., 2008),
whereas mutations of other residues within the binding pocket
(e.g., F195A) decrease or abolish cGMP binding (Sopory et al.,
2003). Based on the presence of helix a2/3 within the b2-b3-con-
necting loop in both high-selectivity GAF A domains from PDE5A
and PDE6C, it appears that this short helix restricts the flexibility
of the Asp/Asn by packing and hydrogen bonding to the back-
bone of the Asp/Asn, causing the side chain to be locked into
position to make cGMP-specific contact (Figure 3E). In contrast,
the b2-b3-connecting loop in the low-specificity PDE2A is
shorter and does not contain secondary structure elements,
whereas the loop in PDE10A is longer but contains short
stretches of b strands that do notmake contact to themain chain
of Asp, allowing it to rotate away from the ligand and make room
for an Arg that makes cAMP-specific contact (Figure 3F). Muta-
tional studies of the b2-b3-connecting loop (and the a2/3-helix)
support such a potential role in providing nucleotide selectivity
(Linder et al., 2007). In all structures, a hydrophobic residue
immediately preceding the Asp/Asn (Phe438 in PDE2A,
Phe195 in PDE5A, Leu115 in PDE6C, and Phe304 in PDE10A)
makes hydrophobic contact with the purine ring of the cNMP
molecule, thereby stabilizing the binding pocket (Figures 3A-3D).
Before the first structure of a cNMP-binding GAF domain was
reported, the so-called NKFDE motif comprised of five strictlyStructureconserved residues found in cNMP-binding GAF domains from
PDEs (Charbonneau et al., 1990; McAllister-Lucas et al., 1995)
was proposed to be essential for nucleotide binding and the
formation of the binding pocket (Ho et al., 2000; Turko et al.,
1996). However, instead of being directly involved in nucleotide
binding, the residues of this motif turned out to be important
for the folding stability of the GAF domain through a network of
hydrogen bonds and salt bridges that are located away from
the binding pocket (Martinez et al., 2002). Furthermore, the motif
is not involved in interdomain interactions in any of the published
crystal structures. All five residues are oriented in practically
identical orientations in the cGMP-bound and cGMP-free forms
of PDE2A GAF B (Pandit et al., 2009), indicating that they do not
play an important role in the nucleotide-dependent conforma-
tional change (see below).
Nucleotide-Dependent Conformational Changes
In all cNMP-bound GAF domain structures, the cyclic nucleotide
is bound in a deeply buried pocket with almost no solvent acces-
sibility. Large rearrangements of secondary structure elements
are necessary to allow cNMP to enter and exit the binding
pocket. This change from ‘‘closed’’ to ‘‘open’’ state was first
demonstrated for the GAF A domains from PDE5A and PDE6C
by NMR studies. In both cases, an increase in domain stability
and a decrease in the overall flexibility upon cGMP binding
was observed (Heikaus et al., 2008; Martinez et al., 2008). Prac-
tically no backbone amide NMR resonances from cGMP-free
GAF A of PDE5A can be observed, suggesting a conformational
exchange that is intermediate on the NMR timescale. Similarly,
the NMR spectra of the cGMP-bound and cGMP -free GAF A
domain of PDE6C significantly differ from each other and reveal
that the core of GAF A adopts two distinctly structured states
with more dynamic elements.
Comparison of the cGMP-bound and cGMP-free GAF B
domain structures of PDE2A reveals that the six-stranded b sheet
and helices a2, a3, a5 are well defined in both forms, whereas no
density could be traced for helix a4, the b4-a4-connecting loop,
and the b2-b3-connecting loop, presumably due to intrinsic
disorder in the absence of cGMP (Figures 4A and 4B) (Pandit17, December 9, 2009 ª2009 Elsevier Ltd All rights reserved 1555
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thereby allowing the nucleotide to enter the open binding pocket.
Of the two helices that provide the roof of the binding pocket
(helices a3 and a4), a3 is significantly less dynamic in the free
structure than a4 (Figures 4A and 4B), a fact that is supported
by H-D exchange data for PDE5A GAF A, which revealed that
a3 is less accessible to solvent exchange than is a4 (Heikaus
et al., 2008).
Together the data suggest that GAF domains undergo a large-
scale ligand-dependent induced fit during which entire sec-
ondary structure elements are stabilized and fixed into position.
Helix a4 and the b2-b3-connecting loop (which in PDE5 and PDE
6 encompasses the short helix a2/3, see above) are dynamic and
sample multiple states. Together, they are responsible for the
closure of the GAF domain upon nucleotide binding. It is likely
that the charged cyclic phosphate group is attracted by the posi-
tive helix dipole created by the N-terminus from the less dynamic
helix a3. Upon binding of the cyclic phosphate group, the binding
pocket closes part of the way over the nucleotide and the cGMP-
and cAMP-specific contacts (see above) lock the specific nucle-
otide into the binding pocket and bury it in the center of the
domain. The flexibility and the large structural rearrangements
within the GAF domains may explain why it has been so difficult
to obtain high-resolution structures of apo GAF domains. Pre-
sumably, the presence of additional sequence elements such
as the catalytic domains and the extensive dimerization interface
along the tandem GAF domains stabilize the apo-GAF B domain
of PDE2A sufficiently for the growth of diffraction-quality crystals
that ultimately led to the full-length PDE2A crystal structure
(Pandit et al., 2009).
Perspectives and Outlook
Recent advances in the structural characterization of cyclic
nucleotide-binding GAF domains from PDEs have answered
several questions. Four of the five cNMP-bound GAF domains
from PDEs have now been described— three of them within
the last year. Furthermore, the crystal structure of full-length
PDE2A represents the first view of a PDE enzyme at high resolu-
tion and puts the regulatory GAF domains in relation to the cata-
lytic domain, something that has long been regarded as the
‘‘Holy Grail’’ in the PDE field. The recent GAF domain structures
represent a major advance, as they provide information about
the molecular determinants of cyclic nucleotide binding and
cNMP-dependent conformational change. Together, they signif-
icantly further our understanding of the GAF domain-dependent
mechanism of PDE regulation.
Nevertheless, several questions about GAF domains and their
functional diversity remain unanswered. The structures reveal
that all GAF domains bind cNMP through a conserved pattern
of interactions with helix dipole-phosphate and hydrophobic
interactions. However, no absolute consensus within the
protein-ligand hydrogen bond network is evident and the struc-
tures reveal that there are various ways to bind cNMPmolecules
with high affinity. Though GAF domains are one of the largest
small molecule-binding domain families, ligand binding has
only been demonstrated for a few GAF domains and the func-
tional significance of tandem GAF domains in PDEs with
a second nonbinding GAF domain also remains to be elucidated.
Among PDEs, the photoreceptor phosphodiesterase 6 is struc-1556 Structure 17, December 9, 2009 ª2009 Elsevier Ltd All rights rturally distinct. Whereas the catalytic subunits of cone PDE6
forms homodimer of a’-subunits, rod PDE6 forms heterodimers
of a- and b-subunits. More structural studies are necessary to
understand the functional significance of this cell-specific differ-
ence and the specific determinants of dimerization. The visuali-
zation of the cNMP-dependent conformational change by
NMR and the comparison of cGMP-free and cGMP -bound
GAF B domain from PDE2A demonstrate the magnitude of the
conformational change that occurs within the GAF domain.
How this large scale induced fit affects the overall conformation
of the full-length enzyme and ultimately causes activation is still
unknown. Additional crystal structures of full-length PDEs,
ideally in several states of activation, are needed to answer this
question.
Cyclic nucleotides play a key role in many important signaling
pathways, and PDEs are the only enzymes that regulate their
concentrations through hydrolysis. Agonists and antagonists
that can modulate catalytic PDE activity by binding to and stabi-
lizing either the ‘‘closed’’ or ‘‘open’’ form of GAF domains have
the potential to be as important therapeutically as the commer-
cially successful catalytic-site inhibitors of PDEs. Among all
PDEs, the sequence conservation and similarities in the cNMP
pocket architecture are lower in GAF domains than in catalytic
domains, suggesting that GAF domain-binding PDE drugs may
have higher PDE selectivity and fewer side effects than cata-
lytic-site inhibitors.
The recently presented GAF domain structures advance the
field significantly and open the door for future investigations.
Determination of complex structures (i.e., PDE6 plus Pg), the
characterization of the mechanistic details of the GAF-depen-
dent regulation of PDEs, and design of GAF-specific drugs will
all be guided by the structures.
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